Autoinflammatory
4 years 1 month ago
Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE
4 years 1 month ago
Next up! #Autoinflammatory diseases: mechanisms and management. First: CRMO & SAPHO with Dr. Polly Ferguson
Highlights:
đź“ŤThe *many* names of CRMO/CNO
đź“ŤClinical features
đź“ŤRx options (NSAIDs, bisphosphonates, TNFi)
đź“ŤRole of innate immunity in etiology
#ACRambassador https://t.co/qP3IySJKGC
4 years 1 month ago
Genotype analysis define new illnesses such as VEXAS.
”Somatic mutation may account for a significant fraction of adult-onset inflammatory disease” says Dr. Dan Castner.
Science enthusiasm at 3S038. Autoinflammatory Diseases.
@petercgrayson #ACR20 <TK https://t.co/gyTxF8NWtO
Fascinating and engaging talk by Dr. Kastner on the discovery of VEXAS using a genotype-first strategy. Definitely one to go back and watch if you missed it! #ACR20 https://t.co/D090V7HiG2
4 years 1 month ago
Dan Kastner giving an absolute tour de force of the discovery of VEXAS in autoinflammatory diseases: mechanisms and management session now. If you aren't listening, watch it back! #ACR20 @rheumnow https://t.co/zell5e2Brt
4 years 1 month ago
Excellent session on #autoinflammatory syndromes #SAPHO syndrome -IL-1 role in disease pathogenesis and something that I ve not come across clinically #Majeed Syndrome @RheumNow #ACR20 #3S038 https://t.co/vnfjPD6Zx9
4 years 1 month ago
Dr Merriman presents on role of diet in gout. It is minor, especially compared to urate lowering therapy. Average attributable fraction approximately 10-fold greater for ULT than following healthy-eating guidelines. @rheumnow #ACR20 Abstr#951 https://t.co/1tftswOEJq
4 years 1 month ago
Dr Cai presents risk of CVD in gout in study 450,000 patients. Gout was independently associated with an increased risk of CVD events HR = 1.24 for women; 1.21 for men. @rheumnow #ACR20 Abstr#950 #ACRbest https://t.co/089aKtN5a7
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of…
4 years 1 month ago
@RheumNow #ACR20 abs0710 early biologic therapy (BT) in JIA: Early BT=better outcome ( 81.8% on TNFi). BT start after 7,5mo from Dx correlates w/higher probability of active disease at 2 yrs (S=0,67 E=0,63). In active group at 2y 75% arthritis, 16,7% uveitis& 8,3% both. #ACRbest